Department of Clinical Medicine and Surgery, Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, ItalyInterests: neuroendocrine neoplasms; neuroendocrine tumors; carcinoid; pheocromocytoma; medullary thyroid cancer; multiple endocrine neoplasia type 1; multiple endocrine neoplasia type 2; pituitary
Department of Public Health, Federico II University of Naples, Naples, Italy.Interests: pituitary neuroendocrine tumors; pituitary adenomas; neuroendocrine neoplasms; neuroendocrine tumors; epigenetic; miRNA; somatostatin receptors; dopamine receptors; cell signalling; cell proliferation and apoptosis
Dear Colleagues,
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with increasing incidence and prevalence, mainly arising in the gastroenteropancreatic tract, but also in the lung, pituitary (Pit-NET) and other organs. Frequent expression on cell surfaces of somatostatin receptors is peculiar in NENs and represents a target for therapy (i.e., somatostatin analogues and peptide-receptor radionuclide therapy). The heterogeneity of NENs is evident in both biological and clinical characteristics. Accordingly, they require a multidisciplinary approach for clinical management while a better insight of pathogenetic mechanisms is needed. In recent years, specialists and researchers from diverse fields have collaborated, striving to enhance the understanding of NENs biology. This collective effort has resulted in the development and diversification of therapeutic approaches for these conditions. Many ongoing studies are expected to further improve our understanding of the biology of NENs along with treatment and diagnosis.
This special issue for Frontiers in Bioscience-Landmark aims to gather research on biological insights and innovations for enhancing NENs patients management. We welcome reviews on cutting edge and original papers exploring recent epigenetic mechanisms in Pit-NETs and NEN pathology. Of special interest are new insights into miRNAs mechanisms of action underlying pathological processes of Pit-NETs and NEN, miRNA-associated therapeutic target discovery, miRNA-associated RNA-based therapy (including miRNAs delivery systems), miRNA biomarkers (including circulating miRNAs), and miRNAs in cell-to-cell communication.
Dr. Roberta Modica and Dr. Claudia Pivonello
Guest Editors
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.